Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + penpulimab in advanced refractory solid tumors
ChiCTR2200056655Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Henan University of Chinese Medicine
- Start
- Feb 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and penpulimab in bronchial carcinoma, hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA) and 1 more, sponsored by First Affiliated Hospital of Henan University of Chinese Medicine. Primary endpoints: Objective response rate, Disease control rate and 1 more. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
anlotinibpenpulimab
03
Conditions
bronchial carcinomahepatocellular carcinoma (HCC)cholangiocarcinoma (CCA)Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2200056655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056655.